z-logo
open-access-imgOpen Access
Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan
Author(s) -
Mao Chih Hsieh,
Chang Lu,
WeiMin Chang,
SzuYuan Wu,
Ping Kun Hsiao,
Tse Jia Liu
Publication year - 2017
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000007306
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , surgery , survival rate , complication , cytoreductive surgery , chemotherapy , ovarian cancer , mortality rate , cancer
Our hospital was the first institution to offer cytoreduction surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiwan. Therefore, we report our experience and outcomes among patients who underwent HIPEC. Since 2002, 164 eligible patients underwent HIPEC, and we excluded cases of laparoscopic or prophylactic HIPEC. The cases were categorized according to whether they were treated before 2012 (Period 1: 80 cases) or after 2012 (Period 2: 84 cases). The rates of surgical morbidity were 46.3% during Period 1 and 20.2% during Period 2 ( P  < .01), and the rates of severe complications were 25% during Period 1 and 9.5% during Period 2 ( P  < .01). The 5-year overall survival rate was 35.8%, with rates of 13.4% for gastric cancer, 27.3% for colon cancer, 70.0% for appendiceal cancer, and 52.4% for ovarian cancer (median follow-up: 34 months). The survival rate was 42.1% when we achieved a cytoreduction score of 0/1, compared with 21.1% in the group with a cytoreduction score of 2/3 ( P  < .01). Severe complications were associated with a 5-year survival rate of 23.4%, compared with 37.9% among cases without severe complications ( P  = .01). Complete cytoreduction was achieved in 78.6% of the patients if they underwent their first surgery at our hospital. We have become an experienced hospital for CRS plus HIPEC. Although our complication rate for CRS plus HIPEC was high, it was within the acceptable range. Long-term survival was achieved in a few cases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here